These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38030231)

  • 21. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
    Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breakthrough SARS-CoV-2 infection in fully vaccinated patients with systemic lupus erythematosus: results from the COVID-19 Vaccination in Autoimmune Disease (COVAD) study.
    Palazzo L; Lindblom J; Kihlgren Olsson E; Nikiphorou E; Wincup C; Saha S; Shaharir SS; Katchamart W; Akarawatcharangura Goo P; Traboco L; Chen YM; Lilleker JB; Nune A; Pauling JD; Agarwal V; Dzifa D; Toro Gutiérrez CE; Caballero-Uribe CV; Chinoy H; ; Agarwal V; Gupta L; Parodis I
    Rheumatol Int; 2024 Oct; 44(10):1923-1933. PubMed ID: 39138675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of COVID-19 vaccination in patients with primary Sjögren's syndrome.
    Verstappen GM; de Wolff L; Arends S; Heiermann HM; van Sleen Y; Visser A; Terpstra JH; Diavatopoulos DA; van der Heiden M; Vissink A; van Baarle D; Kroese FGM; Bootsma H
    RMD Open; 2022 Apr; 8(1):. PubMed ID: 35414631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
    Yuki EFN; Borba EF; Pasoto SG; Seguro LP; Lopes M; Saad CGS; Medeiros-Ribeiro AC; Silva CA; de Andrade DCO; Kupa LVK; Betancourt L; Bertoglio I; Valim J; Hoff C; Formiga FFC; Pedrosa T; Kallas EG; Aikawa NE; Bonfa E
    Arthritis Care Res (Hoboken); 2022 Apr; 74(4):562-571. PubMed ID: 34806342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of the BBIBP-CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort.
    Zamani B; Moradi Hasan-Abad A; Piroozmand A; Dehghani M; Arfaatabar M; Motedayyen H
    Immun Inflamm Dis; 2023 May; 11(5):e858. PubMed ID: 37249277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study.
    Hitchon CA; Mesa C; Bernstein CN; Marrie RA; Card C; O'Brien SF; Kim J
    BMJ Open; 2023 May; 13(5):e071397. PubMed ID: 37253487
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
    Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
    Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
    Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
    Kho MML; Messchendorp AL; Frölke SC; Imhof C; Koomen VJ; Malahe SRK; Vart P; Geers D; de Vries RD; GeurtsvanKessel CH; Baan CC; van der Molen RG; Diavatopoulos DA; Remmerswaal EBM; van Baarle D; van Binnendijk R; den Hartog G; de Vries APJ; Gansevoort RT; Bemelman FJ; Reinders MEJ; Sanders JF; Hilbrands LB;
    Lancet Infect Dis; 2023 Mar; 23(3):307-319. PubMed ID: 36354032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
    Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
    Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. COVID-19 vaccination in autoimmune diseases (COVAD) study: vaccine safety and tolerance in rheumatoid arthritis.
    Naveen R; Parodis I; Joshi M; Sen P; Lindblom J; Agarwal V; Lilleker JB; Tan AL; Nune A; Shinjo SK; Salim B; Ziade N; Velikova T; Edgar Gracia-Ramos A; Saavedra MA; Day J; Makol A; Distler O; Chinoy H; Agarwal V; Aggarwal R; Gupta L; Nikiphorou E;
    Rheumatology (Oxford); 2023 Jul; 62(7):2366-2376. PubMed ID: 36315075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
    Zheng YQ; Li HJ; Chen L; Lin SP
    Sci Rep; 2022 Oct; 12(1):17955. PubMed ID: 36289319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
    Heshin-Bekenstein M; Ziv A; Toplak N; Hagin D; Kadishevich D; Butbul YA; Saiag E; Kaufman A; Shefer G; Sharon O; Pel S; Elkayam O; Uziel Y
    Rheumatology (Oxford); 2022 Nov; 61(11):4263-4272. PubMed ID: 35179569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Use of COVID-19 Vaccines in Patients with SLE.
    Tang W; Gartshteyn Y; Ricker E; Inzerillo S; Murray S; Khalili L; Askanase A
    Curr Rheumatol Rep; 2021 Nov; 23(11):79. PubMed ID: 34767100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. COVID-19 in patients with rheumatological diseases in the Eastern Province of Saudi Arabia.
    Alqatari S; Nemer A; Hasan M; Bukhari R; Al Argan R; Al Khafaji D; Alwaheed A; Alzaki A; Al-Wazza M; Al Warthan S; Al Saeed A; Albeladi F; Almeer H; AlSulaiman R; Abu Quren A
    J Med Life; 2023 Jun; 16(6):873-882. PubMed ID: 37675163
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
    Munro APS; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Gokani K; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kwok J; Lambe T; Libri V; Llewelyn MJ; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Murira J; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Salkeld J; Saralaya D; Sharma S; Sheridan R; Sturdy A; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
    Lancet; 2021 Dec; 398(10318):2258-2276. PubMed ID: 34863358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-COV-2 vaccine responses in renal patient populations.
    Smith RM; Cooper DJ; Doffinger R; Stacey H; Al-Mohammad A; Goodfellow I; Baker S; Lear S; Hosmilo M; Pritchard N; Torpey N; Jayne D; Yiu V; Chalisey A; Lee J; Vilnar E; Cheung CK; Jones RB
    BMC Nephrol; 2022 May; 23(1):199. PubMed ID: 35641961
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of CoronaVac and ChAdOx1 vaccines against SARS-CoV-2 in patients with rheumatoid arthritis: data from the Brazilian multicentric study safer.
    Cruz VA; Guimarães C; Rêgo J; Machado KLLL; Miyamoto ST; Burian APN; Dias LH; Pretti FZ; Batista DCFA; Mill JG; de Oliveira YGP; Gadelha CSE; da Penha Gomes Gouveia M; Moulin ACS; Souza BO; Aguiar LGR; Vieira GSS; Grillo LL; de Lima MD; Pasti LP; Surlo HF; Faé F; Moulaz IR; Macabú MO; Ribeiro PDC; Magalhães VO; de Aguiar MF; Biegelmeyer E; Peixoto FMMMC; Kayser C; de Souza AWS; de Moura Castro CH; Ribeiro SLE; Telles CMPF; Bühring J; de Lima RL; Dos Santos SHO; Dias SEB; de Melo NS; da Silva Sanches RH; Boechat AL; Sartori NS; Hax V; Dória LD; de Rezende RPV; Baptista KL; Fortes NRQ; de Melo AKG; Melo TS; de Abreu Vieira RMR; Vieira ASR; Kakehasi AM; Tavares ACFMG; de Landa AT; da Costa PVT; Azevedo VF; Martins-Filho OA; Peruhype-Magalhães V; de Medeiros Pinheiro M; Monticielo OA; Dos Reis-Neto ET; Ferreira GA; de Souza VA; Teixeira-Carvalho A; Xavier RM; Sato EI; Valim V; Pileggi GS; da Silva NA
    Adv Rheumatol; 2024 Aug; 64(1):58. PubMed ID: 39135131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-SARS-CoV-2 antibodies following vaccination are associated with lymphocyte count and serum immunoglobulins in SLE.
    Reynolds JA; Faustini SE; Tosounidou S; Plant T; Ubhi M; Gilman R; Richter AG; Gordon C
    Lupus; 2023 Mar; 32(3):431-437. PubMed ID: 36631440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis.
    Bartels LE; Ammitzbøll C; Andersen JB; Vils SR; Mistegaard CE; Johannsen AD; Hermansen MF; Thomsen MK; Erikstrup C; Hauge EM; Troldborg A
    Rheumatol Int; 2021 Nov; 41(11):1925-1931. PubMed ID: 34476603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.